Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare - LARVOL DELTA

Indirect Treatment Comparison of Long-Acting Injectable Cabotegravir as Pre-exposure Prophylaxis When Compared with no Pre-exposure Prophylaxis for HIV Prevention. (PubMed, Infect Dis Ther) - "The ITC of cabotegravir versus no PrEP predicted similar estimates of cabotegravir effectiveness in the HPTN 083 and 084 trials, suggesting a very high level of efficacy despite differences in population, setting, underlying rate of HIV acquisition, and oral TDF/FTC adherence. These estimates support the generalizability of the cabotegravir results from both HPTN trials to other populations and regions than those in which these trials were conducted. Graphical abstract available for this article."

Journal • Human Immunodeficiency Virus • Infectious Disease

Seizing the moment: the potential of PrEP choice and innovation to transform HIV prevention. (PubMed, J Int AIDS Soc) - "The new era of PrEP choice, with new long-acting PrEP products and DSD options, presents countries with an extraordinary opportunity to amplify prevention access, achieve higher prevention coverage and drive the meaningful reductions in new HIV acquisitions needed to end the HIV epidemic. Without coordinated and concerted efforts within countries and supported at the global level to leverage choice and embed it within the HIV prevention response, we risk prolonging the HIV epidemic."

Journal • Human Immunodeficiency Virus • Infectious Disease

Estimated impact of long-acting injectable PrEP in South Africa: a model comparison analysis. (PubMed, J Int AIDS Soc) - "Offering CAB-LA in South Africa may substantially impact the HIV epidemic based on these projections. Effective coverage proved to be a good predictor of intervention effectiveness."

Clinical • Journal • Human Immunodeficiency Virus • Infectious Disease

Feasibility and acceptability of persons on long-acting cabotegravir for HIV prevention in the SEARCH Dynamic Choice HIV Prevention trial extension in rural Kenya and Uganda: a longitudinal cohort study. (PubMed, J Int AIDS Soc) - "In rural Uganda and Kenya, over half of participants in the SEARCH trial who were offered choice of oral PrEP/PEP or CAB-LA chose and started CAB-LA during the first 48 weeks. For both males and females and younger and older adults, CAB-LA was both feasible and acceptable to deliver with satisfaction remaining high throughout the study, and nearly all reporting ease of use."

Journal • Human Immunodeficiency Virus • Infectious Disease

Exploring perceptions and preferences for PrEP choice and of an mHealth intervention: insights from the ImPrEP CAB-Brasil study. (PubMed, J Int AIDS Soc) - P3 | "Perceptions for PrEP choice among SGM underscore the importance of providing comprehensive information and support towards decision-making processes, so users can have an accurate understanding of each PrEP option, as well as their clinical and social benefits. The mHealth tool was perceived as highly desirable and useful for PrEP education, having the potential to be implemented in HIV prevention services."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pain

"People have options": a qualitative study of experiences and influences of PrEP choice among women in South Africa. (PubMed, J Int AIDS Soc) - "These findings will guide strategies for PrEP delivery, emphasizing provider training, effective counselling tools and tailored communication. Women valued clear, jargon-free information, visual aids and a welcoming environment, which supported open dialogue. The influence of prior oral PrEP experiences on PrEP choice highlights the need for counselling that addresses specific concerns and preferences."

Journal • Human Immunodeficiency Virus • Infectious Disease

Transforming PrEP marketing: understanding the place of PrEP in the hearts and minds of adolescent girls and young women in sub-Saharan Africa. (PubMed, J Int AIDS Soc) - "This strategic, evidence-informed brand positioning-developed with AGYW, confirms that communication to promote PrEP uptake and continued use must resonate with AGYW's inner strength and frame PrEP use as an act of self-love. It offers a powerful foundation for clear, consistent and inspiring communication that engage and retain AGYW's attention."

Journal • Human Immunodeficiency Virus • Infectious Disease

PrEP preferences and early acceptability of injectable cabotegravir among pregnant and lactating people in Cape Town, South Africa: findings from the PrEPared to Choose study. (PubMed, J Int AIDS Soc) - "PLP in South Africa had a strong preference for CAB-LA over oral PrEP, and CAB-LA was found to be highly acceptable. Further research is needed to evaluate the effect of offering choice of PrEP methods, including CAB-LA, on PrEP continuation among PLP."

Journal • Human Immunodeficiency Virus • Infectious Disease • Pain

Use of cognitive interviews to develop PrEP education for men in New York and Alabama. (PubMed, Patient Educ Couns) - "The training series has the potential to promote shared decision making in a healthcare setting. Feedback collected during cognitive interviews demonstrates the need for clear and comprehensive PrEP educational tools made specifically for patients as well as the need for involvement of the priority intervention audience in the creation of the training materials prior to their release to the public."

Interview • Journal • Human Immunodeficiency Virus • Infectious Disease

EBONI: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (clinicaltrials.gov) - P4 | N=156 | Active, not recruiting | Sponsor: ViiV Healthcare | N=66 ➔ 156

Enrollment change • Human Immunodeficiency Virus • Infectious Disease

Staff Perspectives of Real-World Implementation of Long-Acting Injectable Cabotegravir for Pre-Exposure Prophylaxis at a Low-Barrier Syringe Services Program (CPDD 2025) - "While CAB-LA shows significant promise as an HIV prevention modality for PWID, its implementation at SSPs necessitates efforts to address structural, staffing, and logistical barriers. Implementation strategies such as increased resources, staff capacity building, and flexible service delivery models could improve CAB-LA implementation in SSPs."

Clinical • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

CROI 2025: global epidemiology and prevention of HIV and other sexually transmitted diseases. (PubMed, Top Antivir Med) - "Although the use of long-acting injectable cabotegravir (CAB-LA) remains low in the US, several programs have demonstrated high persistence...PrEP with emtricitabine/tenofovir alafenamide was shown to reduce HIV infections in cisgender women adherent to PrEP. A single once-yearly injection with lenacapavir showed promising pharmacokinetic results and a phase III trial is planned. Interest in doxycycline postexposure prophylaxis is high, and real-world implementation has been associated with significant declines in bacterial sexually transmitted infections."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease

Parrying the Pitfalls of PrEP: Project PEACH (clinicaltrials.gov) - P4 | N=240 | Completed | Sponsor: Emory University | Active, not recruiting ➔ Completed

Trial completion • Human Immunodeficiency Virus • Infectious Disease

Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysis. (PubMed, Lancet Glob Health) - "Our findings suggest that a CAB-LA strategy could reduce transmissions and increase life-years compared with TDF-FTC. The availability of an inexpensive and effective oral alternative medication for adolescent girls and young women in South Africa limits the price that payers should be willing to accept for CAB-LA with a modest markup over TDF-FTC."

HEOR • Journal • Pricing • Human Immunodeficiency Virus • Infectious Disease

Crowdsourcing Ideas for the Implementation of Long-Acting Injectable PrEP among Sexual Minority Men in Chicago through an Innovation Tournament. (PubMed, Implement Sci Commun) - "Given that the co-design of implementation strategies often does not involve the participation of individuals with lived experiences, this work will center the voices of those who will benefit most. Specifically, this research will contribute to the production of implementation strategies co-designed with end users, which can guide plans for CAB-LA integration in Chicago and provide insights for other regions. As the first innovation tournament focused on HIV prevention, this research can provide a framework for participatory approaches across the care continuum."

Journal • Human Immunodeficiency Virus • Infectious Disease

Uptake of Injectable long-acting cabotegravir pre-exposure prophylaxis among Vulnerable Populations in Zambia (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Clinical

One-Year Implementation Outcomes of Cabotegravir Long-Acting Injectable PrEP in Men who Have Sex with Men (MSM) & Transgender Men (TGM): Findings from the PILLAR Study (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Health Care Provider Experiences After 12 Months of Implementing Cabotegravir Long-Acting Injectable PrEP (CAB LA) for Black Women: EBONI Study Results (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Clinical

Retention Patterns of Clients on Long-Acting Injectable Cabotegravir (CAB-LA) and Oral Pre-Exposure Prophylaxis (PrEP) in Zambia: A Comparative Analysis (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Prevalence and incidence of chlamydia and gonorrhoea infections in adolescent females using long acting injectable cabotegravir as HIV pre-exposure prophylaxis in South Africa, Zimbabwe and Uganda: results from HPTN 084-01 (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Human Immunodeficiency Virus • Infectious Disease

Equivalent performance of HIV oral fluid self-testing and rapid testing compared to nucleic acid amplification test in screening adolescents for long-acting injectable cabotegravir in Brazil (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Human Immunodeficiency Virus • Infectious Disease

SY12 Let's get real: Implementing PrEP choice in practice (IAS-HIV 2025) - "Proven PrEP regimens include oral PrEP, two-monthly long-acting injectable cabotegravir, six-monthly long-acting injectable lenacapavir and the dapivirine vaginal ring. While access to these non-oral PrEP options is currently limited, settings all over the world will need to come to grips with practical methods to implement PrEP within a choice framework. This session will focus on practical examples from the real world and large-scale studies on what PrEP choice really means, how to deliver PrEP to the community in the context of multiple options, and tools used in clinical and community settings to implement PrEP choice."

Expanding pre-exposure prophylaxis (PrEP) access: lessons learned from the introduction of PEPFAR supported long-acting injectable cabotegravir (CAB-LA) in shaping global prevention efforts (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

Clinical

Characteristics of early non-persistors on Cabotegravir long-acting (injectable PrEP) compared to persistent users in the PrEPared to Choose study in Cape Town, South Africa (IAS-HIV 2025) - "The embargo on all abstracts, including oral abstract, poster exhibition, e-poster and late breakers, will lift on Monday, 14 July 2025, at 15:30 Central African Time (CAT). If an abstract is part of an official IAS 2025 press conference that occurs before that time, the embargo on that abstract lifts at the start of the official press conference."

A review of pharmacokinetic data describing long-acting injectable cabotegravir during pregnancy. (PubMed, Expert Opin Pharmacother) - "For treatment, CAB-LA is currently approved in combination with long-acting rilpivirine (RPV-LA). Other long-acting prevention and treatment strategies are in development. Future studies assessing long-acting strategies are necessary during drug development to ensure equitable and timely access to novel therapies for all individuals."

Journal • PK/PD data • Review • Human Immunodeficiency Virus • Infectious Disease